BAYER AKTIENGESELLSCHAFT «12345...» Página 1 de 137 desde 01/07/1988 hasta 31/10/2024 18/11/2019 12:50 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Not intended for U.S. and UK Media -Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint Número de registro: 283749 08/11/2019 08:54 BAYER AKTIENGESELLSCHAFT Fixed income issues NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN - Bayer refinances 1.75 billion euro hybrid bond Número de registro: 283442 04/11/2019 14:53 BAYER AKTIENGESELLSCHAFT Transmissions and purchases of capital undertakings Bayer completes sale of Dr. Scholl’s™ brand to Yellow Wood Partners Número de registro: 283260 30/10/2019 08:23 BAYER AKTIENGESELLSCHAFT Strategic plans, profit forecasts and presentations Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health Número de registro: 283025 30/10/2019 08:17 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Q3 2019 Analyst and Investor Briefing Número de registro: 283021 17/10/2019 11:57 BAYER AKTIENGESELLSCHAFT Information on P&L Restatements of Q1-Q4 2018 and Q1-Q2 2019 due to presentation of Animal Health & Currenta as discontinued operations Número de registro: 282642 16/10/2019 11:23 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Q3 2019 Publication Schedule Número de registro: 282606 14/10/2019 16:09 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Not intended for U.S. and UK Media - U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients Número de registro: 282563 01/10/2019 15:25 BAYER AKTIENGESELLSCHAFT Composition of the board of directors Ertharin Cousin to become member of Bayer AG Supervisory Board Número de registro: 282206 30/09/2019 08:37 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Not intended for U.S. and UK Media -Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer Número de registro: 282122 Página 1 de 137 «12345...»